Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.78 |
| ▸ | PPARG | P37231 | 14/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855676 | 0.90 | PPARA (0.80) | PPARAPPARG | |
| SCHEMBL5856029 | 0.88 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5857999 | 0.87 | PPARA (0.63) | PPARAPPARGKDM4EHRH3MEN1 | |
| SCHEMBL5857005 | 0.85 | PPARA (0.82) | PPARAPPARGKDM4E | |
| SCHEMBL5855726 | 0.80 | PPARA (0.80) | PPARAPPARGKDM4EHRH3MEN1 | |
| SCHEMBL5857078 | 0.79 | PPARA (1.00) | PPARAPPARG | |
| SCHEMBL5858424 | 0.78 | PPARA (0.78) | PPARAPPARGHRH3 | |
| SCHEMBL5857394 | 0.76 | PPARA (0.80) | PPARAPPARGKDM4E | |
| SCHEMBL5858210 | 0.76 | PPARA (0.83) | PPARAPPARG | |
| SCHEMBL4248340 | 0.75 | PPARA (1.00) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144906-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-7030143-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-18 | — | — | US | disclosed |
| US-7022723-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| EP-1634876-A2 | Heterocyclic compounds for the treatment of hyperlipidemia agents | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-6998412-B2 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20050009892-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20050009785-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040162325-A1 | Heterocyclic compounds | KUWABARA KENJI (JP) | 2004-08-19 | — | — | US | disclosed |
| US-20030166697-A1 | Heterocyclic compounds | NIPPON SHINYAKU CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295875-A1 | HETEROCYCLIC COMPOUNDS | Nippon Shinyaku Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009785-A1 | Heterocyclic compounds | LIPC, GPR119, APOB | PPARA 464/4885PPARG 393/4885KDM4E 1600/4885 |
| US-20050009892-A1 | Heterocyclic compounds | GPR119, LIPC, LIPE | PPARA 579/4885PPARG 603/4885KDM4E 1141/4885 |
| US-20040162325-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARA 660/4885PPARG 701/4885KDM4E 1321/4885 |
| US-20030166697-A1 | Heterocyclic compounds | LIPE, GPR119, LIPC | PPARA 660/4885PPARG 701/4885KDM4E 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.